Haloperidol (Haldol) |
Category:
Description:
Indications:
-
Psychoses,
Gilles de la Tourette syndrome, severe behavioral problems
-
Hyperactive
children (short term)
-
Prolonged
parenteral neuroleptic therapy for chronic schizophrenia (decanoate)
Contraindications:
Precautions:
-
Pregnancy
category C; has been used for hyperemesis gravidarum, chorea
gravidarum, and manic depressive illness during pregnancy; excreted in
breast milk; effect on nursing infant unknown, but may be of concern
-
Elderly,
severe cardiac disorders, seizure disorder
-
Hepatic
dysfunction, child < 3 years, alcohol withdrawal
-
Abrupt
withdrawal, glaucoma
Adverse
Reactions (Side Effects):
-
CNS:
agitation, anxiety, catatonic-like behavioral states, confusion,
depression, drowsiness, EPS (pseudoparkinsonism, akathisia, dystonia,
tardive dyskinesia), euphoria, exacerbation of psychotic symptoms
including hallucinations, headache, lethargy, neuroleptic malignant
syndrome, restlessness, seizures, vertigo
-
CV:
ECG changes, hypertension, hypotension, tachycardia
-
EENT:
blurred vision, cataracts, dry eyes, glaucoma, retinopathy
-
GI:
anorexia, constipation, diarrhea, dry mouth, dyspepsia,
hypersalivation, nausea, vomiting
-
GU:
priapism, urinary retention
-
HEME:
agranulocytosis, anemia, leukocytosis, minimal decreases in red blood
cell counts, transient leukopenia
-
METAB:
breast engorgement, gynecomastia, hyperglycemia, hyperprolactinemia,
impotence, increased libido, lactation, mastalgia, menstrual
irregularities
-
RESP:
bronchospasm, increased depth of respiration, laryngospasm
-
SKIN:
diaphoresis, loss of hair, isolated cases of photosensitivity,
maculopapular and acneiform skin reactions
|
Dosage:
Administered
orally and intramuscularly
-
Adult:
-
Psychosis/Tourette’s
syndrome: PO 0.5-5mg 2-3 times daily initially depending on
severity of condition, dose is increased to desired dose, max
100mg daily; IM 2-5mg every 1-8 hours
-
Chronic
schizophrenia: IM 10-15 times the individual patient’s
stabilized PO dose every 4 weeks (decanoate)
-
Child
3-12 years:
-
Psychosis: PO/IM 0.05-0.15 mg/kg/day in 2-3 divided doses
-
Tourette’s
syndrome: PO 0.05-0.075 mg/kg/day in 2-3 divided doses
-
Hyperactivity: PO 0.05-0.075 mg/kg/day in 2-3 divided doses
Special
considerations:
Do
not mix liquid formulation with coffee or tea
Use
calibrated dropper
Take
with food or milk
Arise
slowly from reclining position
Do
not discontinue abruptly
Use
a sunscreen during sun exposure to prevent burns
Take
special precautions to stay cool in hot weather
Observe
closely for signs of tardive dyskinesia
|
|
|
|
The information contained here is an
abbreviated summary. For more detailed and complete information, consult the
manufacturer's product information sheets or standard textbooks
Source: Operational Medicine 2001, Health
Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau
of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington,
D.C., 20372-5300
This information is provided by The Brookside Associates. The Brookside
Associates, LLC. is a private organization, not affiliated with any governmental
agency. The opinions presented here are those of the author and do not
necessarily represent the opinions of the Brookside Associates or the Department
of Defense. The presence of any advertising on these pages does not constitute
an endorsement of that product or service by either the US Department of Defense
or the Brookside Associates. All material presented here is unclassified.
C. 2009, 2014, All Rights Reserved
|
|